抗T2DM药治疗阿尔茨海默病研究进展  

Research progress of anti-T2DM drug for treatment of Alzheimer's disease

作　　者：郭爱[1] 宋奇骏 彭鹏[1] 高新宇 陈书仪 赵纲 邓艳秋[1] GUO Ai SONG Qijun PENG Peng GAO Xinyu CHEN Shuyi ZHAO Gang DENG Yanqiu(tDepartment of Pathophysiology, Basic Medical College, Tianjin Medical University, Tianjin 300070, Chin Department of Pathology, Tianjin Medical University Cancer Institute ＆ Hospital, Tianjin 300070, China)

机构地区：[1]天津医科大学基础医学院病理生理教研室,天津300070 [2]天津医科大学肿瘤医院病理科,天津300070

出　　处：《生命的化学》2017年第4期612-616,共5页Chemistry of Life

基　　金：国家自然科学基金项目(81270422;30973156);国家级大学生创新创业训练计划(201610062013);天津医科大学大学生学术研究资助计划项目(创新训练类TMUUROP201603)

摘　　要：阿尔茨海默病(Alzheimer’s disease,AD)的发病机制还不清楚,目前治疗或预防AD的方法效果有限。糖代谢减弱和胰岛素信号紊乱是AD与2型糖尿病(type 2 diabetes mellitus,T2DM)的共同特征,也是T2DM早发AD的主要机制。T2DM相关治疗药物能有效改善AD神经退行性病变,已引起广泛关注。本文总结抗T2DM药物治疗AD研究进展,为AD发病机制和药物研发提供思路。Pathogenesis of Alzheimer＇s disease（AD） is not clear, and the effects of the present method to cure or to prevent AD are limited. AD shares some common features with type 2 diabetes mellitus（T2DM）, such as decreased glucose metabolism and insulin signaling pathway disorder, which may be related to the fact that patients with T2DM usually early get AD. Researches which reported that several drug treating T2DM in clinic could improve pathologic change of AD has drawn extensive attention. The review not only summaries research progress of certain drug curing T2DM for AD but also hope to provide new ideas to understand the pathogenesis of AD and to develop new drug.

关 键 词：阿尔茨海默病 2型糖尿病 胰岛素抵抗 

分 类 号：R749.16[医药卫生—神经病学与精神病学]